| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Haiyun Xu, Xiaoyin Zhuan. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatric disease and treatment. vol 15. 2020-09-30. PMID:31413575. |
the atypical antipsychotics (aaps) have been used as first-line drugs in psychiatric practice for a wide range of psychotic disorders, including schizophrenia and bipolar mania. |
2020-09-30 |
2023-08-13 |
Not clear |
| Raphael J. Leo, Paula Del Regn. Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care. Primary care companion to the Journal of clinical psychiatry. vol 2. issue 6. 2020-09-29. PMID:15014629. |
the atypical antipsychotics appear to be effective for schizophrenia as well as other psychotic disorders, including schizoaffective disorder and mood disorders with psychotic features. |
2020-09-29 |
2023-08-12 |
Not clear |
| Andy R Eugene, Jolanta Masia. Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression. Brain : broad research in artificial intelligence and neuroscience. vol 5. issue 1-4. 2020-09-29. PMID:26609423. |
in this retrospective analysis of electroencephalograms were to identify a surrogate biomarker for the dopamine d2 receptors in the brain by comparing patients diagnosed with schizophrenia taking atypical antipsychotics to depressive patients medicated with selective serotonin reuptake inhibitors. |
2020-09-29 |
2023-08-13 |
Not clear |
| Beatriz Beretta Alves, Giovana de Padua Oliveira, Milton Gabriel Moreira Neto, Roberta Bonamim Fiorilli, Elizabeth do Espírito Santo Cestári. Use of atypical antipsychotics and risk of hypertension: A case report and review literature. SAGE open medical case reports. vol 7. 2020-09-29. PMID:31007920. |
atypical antipsychotics is being considered in the treatment of "negative" symptoms of psychoses, such as schizophrenia. |
2020-09-29 |
2023-08-13 |
Not clear |
| Leslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell, Peter J Weide. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric disease and treatment. vol 15. 2020-09-29. PMID:31564881. |
despite the fact that olanzapine is associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. |
2020-09-29 |
2023-08-13 |
Not clear |
| Jonathan R Scarf. Cariprazine for Schizophrenia and Bipolar Disorder. Innovations in clinical neuroscience. vol 13. issue 9-10. 2020-09-28. PMID:27975000. |
although atypical antipsychotics reduce positive and negative symptoms of schizophrenia as well as manic or mixed episodes of bipolar disorder, they are associated with varying degrees of metabolic adverse effects. |
2020-09-28 |
2023-08-13 |
Not clear |
| I C Miron, F Popescu, V Enăchescu, O M Cristea, E C Stoicănescu, E Amzoiu, M Amzoiu, F D Popesc. Combination of Olanzapine Pamoate with Melatonin and Metformin: Quantitative Changes in Rat Adipose Tissue. Current health sciences journal. vol 45. issue 4. 2020-09-28. PMID:32110439. |
olanzapine is one of the atypical antipsychotics widely used in the treatment of schizophrenia and has been associated with metabolic changes as adverse effects, including hyperglycemia, dyslipidemia, and weight gain. |
2020-09-28 |
2023-08-13 |
rat |
| Andrew T Olagunju, Scott R Clark, Bernhard T Baun. Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome. The Australian and New Zealand journal of psychiatry. vol 53. issue 6. 2020-07-14. PMID:30957510. |
long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome. |
2020-07-14 |
2023-08-13 |
Not clear |
| Sergio Linsambarth, Alvaro Jeria, Keren Avirame, Doron Todder, Raúl Riquelme, Jimmy Stehber. Deep Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia: Beyond an Antidepressant Effect. The journal of ECT. vol 35. issue 4. 2020-06-15. PMID:31764455. |
negative symptoms of schizophrenia show limited response to both typical and atypical antipsychotics. |
2020-06-15 |
2023-08-13 |
Not clear |
| Dominic Pilon, Tony B Amos, Rhiannon Kamstra, Ameur M Manceur, Antoine C El Khoury, Patrick Lefebvr. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. Current medical research and opinion. vol 35. issue 1. 2020-04-27. PMID:30106313. |
short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. |
2020-04-27 |
2023-08-13 |
Not clear |
| Xinyu Fang, Lixian Chen, Dandan Wang, Lingfang Yu, Yewei Wang, Yan Chen, Juanjuan Ren, Wei Tang, Chen Zhan. Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia. Psychiatry research. vol 281. 2020-04-15. PMID:31521045. |
this study aimed to explore the relationship between serum levels of cardiometabolic biomarkers and depressive symptoms in schizophrenia patients treated with atypical antipsychotics. |
2020-04-15 |
2023-08-13 |
human |
| Xue Song, Antoine C El Khoury, Matthew Brouillette, David Smith, Kruti Josh. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of medical economics. vol 22. issue 11. 2020-03-09. PMID:31062998. |
treatment discontinuation of long-acting injectables or oral atypical antipsychotics among medicaid recipients with schizophrenia. |
2020-03-09 |
2023-08-13 |
Not clear |
| Lavanya P Sharma, Y C Janardhan Redd. Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder. Indian journal of psychiatry. vol 61. issue Suppl 1. 2020-02-25. PMID:30745688. |
in addition, certain atypical antipsychotics, clozapine in particular are known to induce or worsen ocs in schizophrenia. |
2020-02-25 |
2023-08-13 |
Not clear |
| Man Li, Weiwen Wang, Lan Sun, Wei Du, Hao Zhou, Feng Sha. Chronic clozapine treatment improves the alterations of prepulse inhibition and BDNF mRNA expression in the medial prefrontal cortex that are induced by adolescent social isolation. Behavioural pharmacology. vol 30. issue 4. 2020-02-13. PMID:30157036. |
clozapine, one of the atypical antipsychotics, is widely used in the treatment of schizophrenia patients and in experimental studies. |
2020-02-13 |
2023-08-13 |
rat |
| Yasushi Yabuki, Lei Wu, Kohji Fukunag. Cognitive enhancer ST101 improves schizophrenia-like behaviors in neonatal ventral hippocampus-lesioned rats in association with improved CaMKII/PKC pathway. Journal of pharmacological sciences. vol 140. issue 3. 2020-02-13. PMID:31474557. |
atypical antipsychotics improve positive and negative symptoms but are not effective for treating cognitive impairments in patients with schizophrenia. |
2020-02-13 |
2023-08-13 |
rat |
| Yi Hang Tay, Jimmy Le. The relationship between serum adiponectin levels, cardiometabolic indices and metabolic syndrome in schizophrenia. Asian journal of psychiatry. vol 43. 2020-02-11. PMID:31059867. |
we hypothesized that serum adiponectin levels are similar in schizophrenia patients and controls, but decreased amongst patients on atypical antipsychotics. |
2020-02-11 |
2023-08-13 |
Not clear |
| Antoine C El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B Amos, Edward Kim, Patrick Lefebvr. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current medical research and opinion. vol 35. issue 3. 2020-02-04. PMID:30526125. |
the prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in medicaid patients with schizophrenia. |
2020-02-04 |
2023-08-13 |
Not clear |
| Antoine C El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B Amos, Edward Kim, Patrick Lefebvr. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current medical research and opinion. vol 35. issue 3. 2020-02-04. PMID:30526125. |
yet, only about 12% of medicaid patients with schizophrenia initiate sga-lais, with poor adherence contributing to frequent relapse among patients on oral atypical antipsychotics (oaas). |
2020-02-04 |
2023-08-13 |
Not clear |
| Raja Lope Adam, Hatta Sidi, Marhani Midin, Hazli Zakaria, Srijit Das, Khairi Che Ma. The Role of Atypical Antipsychotics in Sexuality: Road to Recovery in Schizophrenia. Current drug targets. vol 19. issue 12. 2019-12-13. PMID:28464773. |
the role of atypical antipsychotics in sexuality: road to recovery in schizophrenia. |
2019-12-13 |
2023-08-13 |
human |
| Richard G Frank, Ernst R Berndt, Alisa B Busch, Anthony F Lehma. QUALITY-CONSTANT "PRICES" FOR THE ONGOING TREATMENT OF SCHIZOPHRENIA: AN EXPLORATORY STUDY* The Quarterly review of economics and finance : journal of the Midwest Economics Association. vol 44. issue 3. 2019-11-20. PMID:17710196. |
the composition of treatments for schizophrenia has changed substantially over this six-year time period, toward more intensive use of atypical antipsychotics, and away from psychosocial treatments. |
2019-11-20 |
2023-08-12 |
Not clear |